241 related articles for article (PubMed ID: 10898339)
1. Markers of bone turnover in bone metastases.
Fontana A; Delmas PD
Cancer; 2000 Jun; 88(12 Suppl):2952-60. PubMed ID: 10898339
[TBL] [Abstract][Full Text] [Related]
2. Markers of bone turnover in prostate cancer.
Garnero P
Cancer Treat Rev; 2001 Jun; 27(3):187-92; discussion 193-6. PubMed ID: 11417970
[TBL] [Abstract][Full Text] [Related]
3. Biochemical markers and skeletal metastases.
Demers LM; Costa L; Lipton A
Cancer; 2000 Jun; 88(12 Suppl):2919-26. PubMed ID: 10898335
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
Body JJ; Dumon JC; Gineyts E; Delmas PD
Br J Cancer; 1997; 75(3):408-12. PubMed ID: 9020487
[TBL] [Abstract][Full Text] [Related]
5. Determination and biological relevance of serum cross-linked type I collagen N-telopeptide and bone-specific alkaline phosphatase in breast metastatic cancer.
Kanakis I; Nikolaou M; Pectasides D; Kiamouris C; Karamanos NK
J Pharm Biomed Anal; 2004 Mar; 34(4):827-32. PubMed ID: 15019061
[TBL] [Abstract][Full Text] [Related]
6. Use of markers of bone turnover for monitoring bone metastases and the response to therapy.
Lipton A; Costa L; Ali S; Demers L
Semin Oncol; 2001 Aug; 28(4 Suppl 11):54-9. PubMed ID: 11544577
[TBL] [Abstract][Full Text] [Related]
7. Bone formation and resorption markers as diagnostic tools for bone metastases evaluation.
Galliera E; Luzzati A; Perrucchini G; Gagliano F; Colloredo Mels L; Banfi G; Corsi Romanelli MM; Drago L
Int J Biol Markers; 2012 Dec; 27(4):e395-9. PubMed ID: 23015396
[TBL] [Abstract][Full Text] [Related]
8. Expressiveness of Bone Markers in Breast Cancer with Bone Metastases.
Zulauf N; Brüggmann D; Groneberg D; Oremek GM
Oncology; 2019; 97(4):236-244. PubMed ID: 31412345
[TBL] [Abstract][Full Text] [Related]
9. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
[TBL] [Abstract][Full Text] [Related]
10. Biochemical parameters of bone metabolism in bone metastases of solid tumors (review).
Meijer WG; van der Veer E; Willemse PH
Oncol Rep; 1998; 5(1):5-21. PubMed ID: 9458286
[TBL] [Abstract][Full Text] [Related]
11. Markers of bone turnover for the management of patients with bone metastases from prostate cancer.
Garnero P; Buchs N; Zekri J; Rizzoli R; Coleman RE; Delmas PD
Br J Cancer; 2000 Feb; 82(4):858-64. PubMed ID: 10732759
[TBL] [Abstract][Full Text] [Related]
12. Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report.
Shimozuma K; Sonoo H; Fukunaga M; Ichihara K; Aoyama T; Tanaka K
Jpn J Clin Oncol; 1999 Jan; 29(1):16-22. PubMed ID: 10073146
[TBL] [Abstract][Full Text] [Related]
13. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
14. The clinical use of bone resorption markers in patients with malignant bone disease.
Coleman RE
Cancer; 2002 May; 94(10):2521-33. PubMed ID: 12173317
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of simultaneous determination of bone alkaline phosphatase mass concentration in serum and urinary excretion of pyridinium cross-links for detection of bone metastases.
Withold W; Georgescu G; Khakzad H; Vosberg H; Mueller-Gaertner HW; Reinauer H
Clin Biochem; 1995 Oct; 28(5):511-9. PubMed ID: 8582050
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates in prostate carcinoma.
Adami S
Cancer; 1997 Oct; 80(8 Suppl):1674-9. PubMed ID: 9362435
[TBL] [Abstract][Full Text] [Related]
17. Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer.
Hegele A; Wahl HG; Varga Z; Sevinc S; Koliva L; Schrader AJ; Hofmann R; Olbert P
BJU Int; 2007 Feb; 99(2):330-4. PubMed ID: 17092281
[TBL] [Abstract][Full Text] [Related]
18. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
19. Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation.
Voorzanger-Rousselot N; Juillet F; Mareau E; Zimmermann J; Kalebic T; Garnero P
Br J Cancer; 2006 Aug; 95(4):506-14. PubMed ID: 16880790
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of bone formation markers in breast cancer.
Palma MA; Body JJ
Int J Biol Markers; 2005; 20(3):146-55. PubMed ID: 16240842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]